International nonproprietary name: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 27: | Line 27: | ||
[[Category:Drug safety]] | [[Category:Drug safety]] | ||
{{No image}} | {{No image}} | ||
Latest revision as of 17:28, 18 March 2025
International Nonproprietary Name (INN) is a unique name that is globally recognized and is used to identify pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is intended to be used universally to identify a pharmaceutical substance. The use of INNs facilitates the clear identification, safe prescription, and dispensing of medicines to patients and also provides a standard to pharmacists and researchers.
Overview[edit]
The concept of the INN system was introduced by the World Health Organization (WHO) in 1953 to provide a universal and unique identifier for pharmaceutical substances. The aim was to ensure that each active ingredient of a drug had a single name that would be recognized globally, irrespective of the brand names under which it might be sold. This system helps to avoid confusion, which can lead to medication errors caused by the numerous drug names that vary from country to country and even between manufacturers in the same country.
Selection of INNs[edit]
The selection of an INN starts with a proposal made by the manufacturer or discoverer of the substance. The proposed names are then evaluated by experts in the WHO's INN Programme, who consider factors such as ease of pronunciation, potential for confusion with other names, and suitability for use in different languages. The proposed INN is then published in the WHO Drug Information journal, allowing for comments and objections to be raised by interested parties. If no objections are raised, the name is formally adopted as an INN.
Structure of INNs[edit]
INNs are usually composed of a prefix, stem, and sometimes a suffix. The stem indicates the nature of the pharmaceutical substance, its action, or its therapeutic use. For example, the stem "-prazole" is used for proton pump inhibitors, and "-artan" is used for angiotensin II receptor antagonists. The prefix is unique for each substance and is chosen so as not to be misleading or to imply an unwarranted therapeutic claim. The suffix, when present, provides additional information about the chemical or pharmacological properties of the substance.
Benefits of the INN System[edit]
The INN system provides several benefits, including:
- Facilitating the clear identification of pharmaceutical substances, thereby reducing medication errors.
- Providing a standard nomenclature that is independent of commercial interests.
- Enabling health professionals and patients to communicate more effectively about medications.
- Assisting in the regulation and safe use of medicines across different countries.
Challenges and Limitations[edit]
While the INN system plays a crucial role in global health, it faces challenges such as the need for continuous updating to accommodate new substances and the potential for confusion with similar-sounding names. Additionally, the adoption of INNs does not eliminate the use of brand names by pharmaceutical companies, which can still lead to confusion among patients and healthcare providers.
Conclusion[edit]
The International Nonproprietary Name system is a vital component of global healthcare, ensuring the safe and effective identification and use of medicines. By providing a standardized nomenclature for pharmaceutical substances, the INN system supports the safe prescription and dispensing of medicines, thereby contributing to patient safety and public health.